Cover Image
市場調查報告書

Frontier Pharma:類風濕性關節炎 - 細胞因子介質及激化酵素抑制劑支配First-in-Class產品的創新

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

出版商 GBI Research 商品編碼 367992
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
Frontier Pharma:類風濕性關節炎 - 細胞因子介質及激化酵素抑制劑支配First-in-Class產品的創新 Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation
出版日期: 2016年08月01日 內容資訊: 英文 66 Pages
簡介

本報告提供類風濕性關節炎市場相關調查分析,提供您革新案例,臨床·商業性情形,開發中產品的評估,計劃評估,最近的交易等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 革新案例

  • 生技藥品的機會擴大
  • 分子標的多樣化
  • 開發創新的First-in-Class產品 (劃時代的醫藥品)在現在也極具吸引力
  • 法規·給付政策有利於First-in-Class產品的革新
  • 持續性的革新
  • 報告指南

第4章 臨床·商業性情形

  • 疾病概要
  • 症狀
  • 流行病學
  • 病因
  • 病理學
  • 合併症·併發症
  • 診斷
    • 血液檢驗
    • 1987年 類風濕性關節炎的分類
    • 2010年 類風濕性關節炎的ACR-EULAR分類標準
  • 病的進展
  • 治療選擇·治療流程
  • 類風濕性關節炎的上市產品概要

第5章 開發中產品革新的評估

  • 類風濕性關節炎的開發平台:開發階段,分子類型,治療標的別
  • 類風濕性關節炎市場及開發平台間的計劃的分佈比較:治療標的各系列
  • 以新分子標的為目標的First-in-Class計劃

第6章 信號 (信號傳達) 網路,疾病的因果關係,革新的調整

  • 類風濕性關節炎的信號網路複雜
  • 信號途徑,病原因的變形,及First-in-Class分子標的整合
  • First-in-Class的矩陣評估

第7章 First-in-Class標的評估

  • 以腫瘤壞死因子受體超級家族成員5(CD40)為標的開發平台計劃
  • 以非受體酪胺酸蛋白質激酶 (TYK2) 為標的開發平台計劃
  • 以IL-10 及 IL-18為標的開發平台計劃 、其它

第8章 策略性整合

  • 產業整體First-in-Class交易
  • 許可證交易
  • 共同開發交易
  • 末參與許可證或共同開發交易的First-in-Class計劃

第9章 附錄

圖表

目錄
Product Code: GBIHC395MR

Executive Summary

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium - the soft tissue of the joint - leading to pain, joint stiffness, and eventually deformity and disability.

With the disease affecting 0.3-1.0% of the global population, the societal and economic costs of RA are substantial. The large target patient population and the relatively high annual cost of therapy have resulted in a crowded, highly lucrative market.

Treatment options have improved and diversified substantially over the past two decades, largely owing to the advent of biologics. Despite this, considerable unmet needs remain within RA. Consequently, opportunities for future drug developments remain significant, particularly for first-in-class innovation, which is the area most likely to produce substantial clinical advances.

Scope

Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.

  • What is the pathophysiology of RA?
  • Which products and therapeutic strategies dominate the clinical and commercial landscapes?
  • What are the most significant unmet needs within the RA market?

Considerable diversification from current market trends is evident within the RA pipeline.

  • Which molecular targets are most prominent within the pipeline?
  • What proportion of pipeline products are first in class?
  • Which first-in-class targets are most promising?

Deal values for licensing and co-development deals vary considerably.

  • How many strategic consolidations have been completed in the past decade?
  • Which types of assets attract the largest deal values?
  • Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

This report will allow you to -

  • Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options.
  • Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market.
  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the RA pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
  • Identify first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. A Crowded, Competitive Market, with Significant Unmet Needs Remaining
  • 2.2. Early-Stage Pipeline Offers Greatest Promise for First-in-Class Innovation
  • 2.3. Cytokine and Cytokine Receptors, as well as Protein Kinases, Largely Dominate First-in-Class Pipeline Products

3. The Case for Innovation

  • 3.1. Growing Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Development Remains Attractive
  • 3.4. Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
  • 3.5. Sustained Innovation
  • 3.6. GBI Research Report Guidance

4. Clinical and Commercial Landscape

  • 4.1. Disease Overview
  • 4.2. Disease Symptoms
  • 4.3. Epidemiology
  • 4.4. Etiology
  • 4.5. Pathophysiology
  • 4.6. Co-morbidities and Complications
  • 4.7. Diagnosis
    • 4.7.1. Blood Tests
    • 4.7.2. 1987 Rheumatoid Arthritis Classification
    • 4.7.3. 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis
  • 4.8. Disease Progression
  • 4.9. Treatment Options and Treatment Algorithm
  • 4.10. Overview of Marketed Products in Rheumatoid Arthritis
    • 4.10.1. Molecule Type and Molecular Target Analysis

5. Assessment of Pipeline Product Innovation

  • 5.1. Rheumatoid Arthritis Pipeline by Stage of Development, Molecule Type and Molecular Target
  • 5.2. Comparative Distribution of Programs between the Rheumatoid Arthritis Market and Pipeline by Therapeutic Target Family
  • 5.3. First-in-Class Programs Targeting Novel Molecular Targets

6. Signaling Network, Disease Causation and Innovation Alignment

  • 6.1. Complexity of Signaling Networks in Rheumatoid Arthritis
  • 6.2. Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
  • 6.3. First-in-Class Matrix Assessment

7. First-in-Class Target Evaluation

  • 7.1. Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5(CD40)
  • 7.2. Pipeline Programs Targeting Non-Receptor Tyrosine-Protein Kinase TYK2(TYK2)
  • 7.3. Pipeline Programs Targeting IL-10 and IL-18
  • 7.4. Pipeline Programs Targeting 72 kDa Type IV Collagenase(MMP2)
  • 7.5. Pipeline Programs Targeting P2X Purinoceptor 7(P2RX7)
  • 7.6. Pipeline Programs Targeting Protein Kinase C Theta Type(PRKCQ)
  • 7.7. Pipeline Programs Targeting C-C Motif Chemokine 4(CCL4) and C-C Motif Chemokine 5(CCL5)
  • 7.8. Pipeline Programs Targeting C-X-C Motif Chemokine 10(CXCL10) and C-X-C Motif Chemokine 13(CXCL13)

8. Strategic Consolidations

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Licensing Deals
  • 8.3. Co-development Deals
  • 8.4. First-in-Class Programs Not Involved in Licensing or Co-development Deals

9. Appendix

  • 9.1. References
  • 9.2. Abbreviations
  • 9.3. Research Methodology
  • 9.4. Secondary Research
    • 9.4.1. Market Analysis
    • 9.4.2. Pipeline Analysis
    • 9.4.3. First-in-Class Matrix Assessment
    • 9.4.4. First-in-Class Target Profiles
    • 9.4.5. Licensing and Co-Development Deals
  • 9.5. Contact Us
  • 9.6. Disclaimer

List of Tables

  • Table 1: 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis, 2010
  • Table 2: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40), 2016
  • Table 3: Rheumatoid Arthritis, Global, Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40), 2016
  • Table 4: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of Tyrosine-Protein Kinase TYK2 (TYK2), 2016
  • Table 5: Rheumatoid Arthritis, Global, Pipeline Programs Targeting Tyrosine-Protein Kinase TYK2 (TYK2), 2016
  • Table 6: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of Interleukin 18, 2016
  • Table 7: Rheumatoid Arthritis, Global, Pipeline Programs Targeting Interleukin 18, 2016
  • Table 8: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of Interleukin 10, 2016
  • Table 9: Rheumatoid Arthritis, Global, Pipeline Programs Targeting Interleukin 10, 2016
  • Table 10: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of 72 kDa type IV collagenase (MMP2), 2016
  • Table 11: Rheumatoid Arthritis, Global, Pipeline Programs Targeting 72 kDa type IV collagenase (MMP2), 2016
  • Table 12: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of P2X Purinoceptor 7 (P2RX7), 2016
  • Table 13: Rheumatoid Arthritis, Global, Pipeline Programs Targeting P2X Purinoceptor 7 (P2RX7), 2016
  • Table 14: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of Protein Kinase C Theta Type (PRKCQ), 2016
  • Table 15: Rheumatoid Arthritis, Global, Rheumatoid Arthritis, Global, Pipeline Programs Targeting Protein Kinase C Theta Type (PRKCQ), 2016
  • Table 16: Rheumatoid Arthritis, Global, Rheumatoid Arthritis, Global, Pipeline Programs Targeting C-C Motif Chemokine 4 (CCL4), 2016
  • Table 17: Rheumatoid Arthritis, Global, Rheumatoid Arthritis, Global, Pipeline Programs Targeting C-C Motif Chemokine 5 (CCL5), 2016
  • Table 18: Rheumatoid Arthritis, Global, Rheumatoid Arthritis, Global, Pipeline Programs Targeting C-C Motif Chemokine 4 (CCL4) and C-C Motif Chemokine 5 (CCL5), 2016
  • Table 19: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of C-X-C Motif Chemokine 10, 2016
  • Table 20: Rheumatoid Arthritis, Global, Pipeline Programs Targeting C-X-C Motif Chemokine 10, 2016
  • Table 21: Rheumatoid Arthritis, Global, Key Features and Pipeline Activity of C-X-C Motif Chemokine 13, 2016
  • Table 22: Rheumatoid Arthritis, Global, Pipeline Programs Targeting C-X-C Motif Chemokine 13 (CXCL13), 2016

List of Figures

  • Figure 1: Rheumatoid Arthritis, US, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals, 1987-2012
  • Figure 2: Rheumatoid Arthritis, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval ($m), 2006-2013
  • Figure 3: Rheumatoid Arthritis, Global, Marketed Products by Molecule Type and Molecular Target, 2016
  • Figure 4: Rheumatoid Arthritis, Global, Pipeline by Stage of Development and Molecule Type, 2016
  • Figure 5: Rheumatoid Arthritis, Global, Pipeline by Molecular Target and Stage of Development, 2016
  • Figure 6: Rheumatoid Arthritis, Global, Pipeline by Key Molecular Target Groups, 2016
  • Figure 7: Rheumatoid Arthritis, Global, Distribution of Molecular Targets Across Pipeline and Marketed Products, 2016
  • Figure 8: Rheumatoid Arthritis, Global, Distribution of Pipeline First-in-Class and Established Molecular Targets, 2016
  • Figure 9: Rheumatoid Arthritis, Global, Percentage Distribution of First-in-Class and Established Pipeline Products by Stage of Development (%), 2016
  • Figure 10: Rheumatoid Arthritis, Global, Percentage Distribution of First-in-Class and Established Pipeline Products by Molecular Target (%), 2016
  • Figure 11: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 1)
  • Figure 12: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 2)
  • Figure 13: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 3)
  • Figure 14: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 4)
  • Figure 15: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 5)
  • Figure 16: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 6)
  • Figure 17: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 7)
  • Figure 18: Rheumatoid Arthritis, Global, Pipeline Products, 2016 (part 8)
  • Figure 19: Rheumatoid Arthritis, Global, First-in-Class Molecular Target Matrix Assessment, 2016 (part 1)
  • Figure 20: Rheumatoid Arthritis, Global, First-in-Class Molecular Target Matrix Assessment, 2016 (part 2)
  • Figure 21: Rheumatoid Arthritis, Global, First-in-Class Molecular Target Matrix Assessment, 2016 (part 3)
  • Figure 22: Rheumatoid Arthritis, Global, Industry-Wide Deals by Stage of Development, 2006-2014
  • Figure 23: Rheumatoid Arthritis, Global, Industry-Wide Licensing Deals by Deal Value ($m), Upfront Payment Value ($m) and Stage of Development, 2006-2014
  • Figure 24: Rheumatoid Arthritis, Global, Licensing Deals by Region and Deal Value ($m), 2006-2016
  • Figure 25: Rheumatoid Arthritis, Global, Disclosed and Undisclosed Licensing Deals by Year, Total Disclosed Deal Value ($m) and Total Upfront Payment Value ($m), 2006-2015
  • Figure 26: Rheumatoid Arthritis, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016
  • Figure 27: Rheumatoid Arthritis, Frequency and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, Global, 2006-2016
  • Figure 28: Rheumatoid Arthritis, Global, Co-development Deals by Region and Deal Value ($m), 2006-2016
  • Figure 29: Rheumatoid Arthritis, Global, Disclosed and Undisclosed Co-development Deals by Year, Total Disclosed Deal Value ($m) and Total Upfront Payment Value ($m), 2006-2015
  • Figure 30: Rheumatoid Arthritis, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2016
  • Figure 31: Rheumatoid Arthritis, Global, Frequency and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2016
  • Figure 32: Rheumatoid Arthritis, Global, First-in-Class Programs with No Recorded Prior Deal Involvement, 2016 (part 1)
  • Figure 33: Rheumatoid Arthritis, Global, First-in-Class Programs with No Recorded Prior Deal Involvement, 2016 (part 2)
Back to Top